FDA Approves Bayer XIa Inhibitor Sunharbo for Secondary Stroke Prevention

The approval introduces the first drug in a new class that targets factor XIa to interrupt thrombosis while theoretically sparing hemostasis. In the pivotal trial, 53 patients needed treatment for one year to prevent one recurrent ischemic stroke. Absolute risk fell 2.2 percentage points, a relative reduction of 26%. Prior anticoagulants have been limited in this population because of intracranial hemorrhage risk, so the new mechanism addresses an unmet need after initial stroke or TIA.

Context from related trials of other XIa inhibitors shows consistent signals of lower bleeding than factor Xa inhibitors, yet none have yet demonstrated superiority on hard clinical endpoints in large head-to-head studies. Real-world uptake will depend on post-approval surveillance for rare bleeding events and on whether payers require failure of dual antiplatelet therapy first. Guidelines committees are expected to review the data within 12 months.

Next steps include Bayer’s planned outcomes trial in atrial fibrillation and an FDA-mandated pregnancy registry. Long-term questions remain about durability of benefit beyond one year and net clinical benefit when combined with antiplatelet agents.